Chapter 53: Drugs That Help Normalize Cholesterol and Triglyceride Levels

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Usually when you think about like a plumbing problem, there's a pretty clear expectation of how it gets fixed.

Right?

Oh yeah.

Like unclog the pipe and you're good to go.

Exactly.

You have a clogged pipe, the clumber comes in, clears the blockage, and the water flows again.

It's binary.

It's clogged.

Or it's not clogged.

It's a simple mechanical fix.

I mean, we like things to be visible and straightforward.

Right, but then you look at the human cardiovascular system and suddenly that simple plumbing analogy just completely falls apart.

Yeah, it really does.

You can't just, you know, snake a coronary artery.

Right.

We're looking at this microscopic chemical traffic jam that takes decades to build up.

Yeah.

And the manual to fix it is incredibly dense.

I mean, it is the absolute definition of physiological muddy waters.

Oh, absolutely.

And if you are a nursing student listening to this right now, prepping for a pharmacology exam or getting ready to step out on the clinical floor,

navigating those muddy waters is your mission today.

That's right.

Because we are doing a deep dive into the complex pharmacology of drugs that help normalize cholesterol and triglyceride levels.

And this is straight from chapter 53 of Lenn's Pharmacology for Nursing Care.

And we have a really clear blueprint for this deep dive too.

We'll start by understanding the villains and the vehicles, meaning, you know, cholesterol, the lipoproteins that carry it through the blood, and the exact biological cascade that causes atherosclerosis.

The actual plaque buildup.

Exactly.

From there, we'll explore how clinicians use screening guidelines to assess risk.

And finally, we will break down the pharmacology of the major drug classes.

The heavy hitters.

Right.

We'll explore their exact mechanisms of action, the side effects, and like most importantly, the nursing implications you need to actually keep your patients safe.

And just a quick tone check before we jump into the deep end here.

Please do not stress about the dense drug charts and all those complex metabolic pathways in this chapter.

Yeah, don't let it overwhelm you.

We are going to translate all of that into tight cause and effect clinical reasoning.

So when you get that exam question, or, you know, when a patient asks you why their legs hurt after starting a new pill, you'll know the precise biological reason why.

Are we ready?

So, let's begin with the physiology of lipids.

Where does this cholesterol story actually begin?

Well, it begins with a bit of myth -busting, honestly, because the text emphasizes that cholesterol isn't inherently evil.

Right, it gets a bad rap.

It does.

But it is absolutely vital for human life.

We need it to build the plasma membranes of our cells to synthesize hormones like estrogen, progesterone, and testosterone.

And we need it for digestion, right?

Yes, to make bile salts in the liver, which we require to digest dietary fats, so it's essential.

But where is the body getting it?

I mean, I know dietary intake is part of the equation.

Right, so dietary intake is the exogenous source, but the vast majority of our cholesterol is actually endogenous.

Meaning we make it ourselves.

Exactly.

Our own cells manufacture it primarily right in the liver.

And the liver uses a very specific enzyme to synthesize this cholesterol called HMG -K -Way reductase.

HMG -K -Way reductase.

Okay, I'm putting a pin in that one.

Definitely put a pin in that enzyme because it's going to be the central target of our most important drugs later on.

Consider it pinned.

Now, here's something that always trips people up.

The reading points out that eating a bunch of dietary cholesterol doesn't actually spike your blood cholesterol all that much.

Why is that?

It really comes down to a physiological negative feedback loop.

So when you eat more cholesterol, your liver senses that increase in the blood and it just, well, it down regulates its own production.

Oh, so it just produces less to keep the balance.

Right.

However, if you eat an excess of saturated fats, that's the real issue.

Your liver uses those saturated fats as the raw building blocks to make a substantial amount of endogenous cholesterol.

Wow.

Yeah.

That can produce a 15 to 25 % increase in circulating cholesterol.

So cutting saturated fats is far more critical than just avoiding dietary cholesterol itself.

Got it.

Exactly.

Now, cholesterol is a lipid, which means it's a fat and blood is an aqueous solution, right?

It's mostly water.

Right.

And oil and water don't mix.

Exactly.

So how does this cholesterol travel through the bloodstream without just clumping up into a giant greasy mess?

Well, because lipids aren't water soluble, they have to travel inside this highly specialized transport shell and these structures are called lipoproteins.

You know, I find the analogy of a cream filled chocolate truffle works perfectly here.

Oh, I like that.

Let's hear it.

So the creamy center of the lipoprotein is the hydrophobic core.

That's where the cholesterol and the triglycerides are hidden safely away from the water in the blood.

Right.

They hate water.

Exactly.

And the chocolate shell on the outside is a hydrophilic, water -loving phospholipid layer that lets the whole structure just dissolve and float smoothly down the bloodstream.

That is an excellent visual.

And if we look closely at the outside of that truffle, it has these little protein structures embedded in the outer shell called apolipoproteins.

Apolipoproteins.

Yeah.

They basically function like recognition tags or shipping labels.

They tell the cells in your body, you know, hey, I have a delivery of cholesterol, open up your receptors and let me in.

So they're like barcodes.

Exactly.

And epiloprotein B100 is one of the most significant tags to remember for our bad cholesterol.

OK.

So let's talk about the different delivery trucks on this highway, because the text breaks down several classes of lipoproteins.

Let's translate those clinical abbreviations.

First up are VLDLs, or very low -density lipoproteins.

Right.

So VLDLs are interesting because they mostly carry triglycerides, not cholesterol.

Oh, OK.

Yeah.

And their exact role in causing atherosclerosis is, well, it's a little fuzzy.

But what we do know for sure is the clinical danger they pose.

Which is what?

Extremely high levels of triglycerides, and we're talking over 500 milligrams per deciliter, will cause severe acute pancreatitis.

Wow.

500.

That's high.

It is.

The body breaks down those excess triglycerides and the pancreatic capillaries into free fatty acids, and those are highly toxic to the pancreas.

OK.

So that's the VLDLs.

Next we have the infamous LDLs, or low -density lipoproteins.

Right.

These are the primary cholesterol carriers in the blood, and they are the ones utilizing that B100 tag we just mentioned.

The bad guys.

Universally recognized as the bad cholesterol, yes.

LDLs definitely initiate and fuel the progression of atherosclerosis.

And finally, HDLs, high -density lipoproteins, the so -called good cholesterol.

How do these differ?

They are beneficial because their transport function is essentially reversed.

What do you mean by reversed?

Well, instead of dropping cholesterol off at your tissues, HDLs carry cholesterol away from the peripheral tissues.

They grab it and bring it back to the liver to be processed and removed from the body.

Like a garbage truck.

Exactly.

This reverse transport actively protects against cardiovascular disease.

So knowing what these lipid transport vehicles are, what actually happens when there are just too many of those LDL delivery trucks on the road?

The text walks through the pathogenesis of atherosclerosis.

And honestly, it's a lot more violent than just a simple pipe getting clogged.

Oh, it is a highly inflammatory cascade.

It's not passive at all.

Walk me through it.

So when you have an excessive concentration of LDL in the blood, those particles penetrate the inner lining of the arterial wall, the endothelium, and they get stuck in the subendothelial space.

And they don't just sit there peacefully, do they?

Not at all.

Once they're trapped, the LDL undergoes oxidation.

And this oxidized LDL is perceived by the body as toxic and foreign.

So the alarm bells go off.

Exactly.

It triggers a chronic inflammatory response.

Your immune system sends in macrophages, which are these large white blood cells, to clean up the mess.

The cleanup crew.

Right.

And the macrophages just eat and eat the oxidized LDL particles until they become so engorged with fat that they're literally called foam cells under a microscope.

Foam cells.

That sounds awful.

It is.

And as those foam cells accumulate in the arterial wall, they create this visible fatty streak.

And that physical lump causes the blood flowing past it to become turbulent, right?

Exactly.

And the turbulence causes more mechanical damage, which leads to more inflammation.

Then smooth muscle cells migrate to the area, collagen is laid down, and the streak grows into a mature fibrous plaque with an acratic core.

And here is the critical danger that every nurse needs to understand right from the chapter.

The size of the plaque isn't actually the main issue.

No, it's really not.

It's the stability of the fibrous cap covering it.

If that cap is weak or inflamed, the sheer force of the blood flowing past it can cause the plaque to rupture.

And when it ruptures, all that highly thrombogenic material inside the core is suddenly exposed to the blood.

And boom, platelets rush in immediately.

A blood clot or a thrombus forms in literally seconds, and you have a total arterial blockage.

If that happens in a coronary artery, it causes a myocardial infarction, a heart attack.

If it happens in a cerebral artery, it causes a stroke.

So knowing how these fat -laden foam cells create this dangerous plaque, how does a clinician know who is at risk before the plaque actually ruptures?

Because the clinical guidelines laid out in the text for screening are actually quite surprising.

They really are.

The 2018 ACCHA guidelines emphasize that screening starts incredibly early.

How early?

Children between the ages of 9 and 11 get a baseline lipid screening.

Nine years old.

I mean, that highlights just how cumulative this disease process really is.

It takes decades to build that plaque.

It does.

It's a lifelong process.

For adults, clinicians use risk assessment tools like the Framingham Risk Prediction Score.

Okay, what does that do?

This calculates a patient's absolute risk of having a major coronary event in the next 10 years.

It factors in their age, total cholesterol, smoking status, HDL levels, and systolic blood pressure.

And there is a vital nerthing concept here regarding diabetes.

The text says diabetes isn't just a risk factor anymore, right?

Right.

It is classified as an ASCVD risk equivalent.

Risk equivalent.

Meaning what?

Practically.

That means if a patient has diabetes, the long -term vascular damage caused by hyperglycemia makes their statistical risk of a cardiovascular event so high that they are treated proactively As if they already have clinical heart disease.

Exactly.

You treat them like they've already had an event.

So if a patient gets a high Framingham Score or they have diabetes, what's the first step?

Do we immediately start them on a statin prescription?

No.

The clinical algorithm dictates that therapeutic lifestyle changes, or TLCs, are always the first -line intervention.

We don't jump straight to drugs.

So what are the TLCs?

They include a diet low in saturated fats, daily aerobic exercise, weight control, and absolute smoking cessation.

But you know, the reality of nursing practice is that lifestyle changes often aren't enough.

Or maybe the patient has a genetic predisposition driving their numbers up.

Yeah, genetics plays a huge role.

So when TLCs fail, we bring in the heavy hitters.

Let's transition into the pharmacology, starting with the undisputed MVP class of the chapter of the statins.

Also known formally as HMG -CoA reductase inhibitors.

This class includes atorvastatin, simvastatin, rosuvastatin.

Statins.

Right.

These are the most effective, most widely prescribed drugs for lowering LDL cholesterol.

And they also have the secondary benefit of slightly raising HDL and lowering triglycerides.

They also provide non -lipid benefits, right?

Like they help stabilize those fragile fibrous plaques we talked about earlier.

Yes.

They improve endothelial function and actively reduce inflammation at the site of the plaque.

But I want to push back on the mechanism of action here, because the textbook presents what sounds like a biological paradox.

Oh, I know exactly what you're going to say.

It states that statins inhibit HMG -CoA reductase, the liver's cholesterol factory.

But then it says in response to that inhibition, the liver just synthesizes more of the HMG -CoA reductase enzyme.

Right.

So if the liver just fights back and makes more of the enzyme, how does the drug actually work long term?

That is a brilliant observation.

And it's a classic exam trap for nursing students.

And can trap us.

The primary action inhibiting the enzyme isn't what ultimately lowers the blood cholesterol.

It's the secondary compensatory effect that does the heavy lifting.

Break that down for me.

What is the liver actually doing?

Well, because the liver's internal cholesterol production is temporarily starved by the statin, the liver panics.

I mean, it still requires cholesterol to survive and make bile.

Right.

So the hepatocytes synthesize thousands of new LDL receptors and embed them on their outer cell surface.

Oh, I see.

Yeah.

And these receptors act like biological magnets.

They actively pull the existing circulating LDL out of the bloodstream and into the liver for processing.

So more receptors on the liver equals less LDL in the blood.

Exactly.

That is the tight cause and effect mechanism you need to remember.

That makes perfect sense.

Let's discuss clinical considerations and nursing implications for statins.

First, timing of administration.

When should patients take these?

Statins should generally be administered in the evening.

Why the evening?

The rationale is tied to our diurnal rhythm.

So endogenous cholesterol synthesis peaks during the night while we sleep.

You want the drug concentration at its peak when the liver's factory is working the hardest.

Oh, that's really clever.

What about patient demographics?

Are there specific pharmacokinetic warnings based on genetics?

Yes.

The text highlights a very specific warning for rosevastatin in patients of Asian descent.

What happens with them?

For these patients, the drug is cleared from the body much more slowly.

So it leads to abnormally high blood levels.

So they need a different dose.

Right.

You must start with a significantly lower dose and monitor them very closely for toxicity.

Let's address those adverse effects.

Because statins are usually well tolerated, but there are two profound dangers every nurse must watch for.

The first is hepatotoxicity.

Statins can cause liver injury, so the standard of care requires drawing baseline liver function tests, or LFTs, before starting therapy.

And teaching the patient what to look for, right?

Absolutely.

Instructing them to report any signs of liver damage, like jaundice or dark urine.

Okay, what's the second danger?

The second and most critical for daily nursing assessment is myopathy.

Muscle aches.

Yes.

Mild muscle aches are relatively common, but rarely this progresses to a fatal condition called rhabdomyolysis.

Rhabdo.

That's terrifying.

It is a severe disintegration of muscle tissue.

And as the muscle fibers break down, they release a protein called myoglobin into the blood, along with massive amounts of an enzyme called creatine kinase, or CK.

Wait, why is releasing myoglobin so fatal?

Because myoglobin is a really large molecule.

As that muscle debris travels through the blood and gets filtered by the kidneys, the myoglobin gets physically lodged in the renal tubules.

Oh no.

So it plugs up the kidneys.

Yes, causing acute renal failure.

So if a patient on a statin reports unexplained muscle pain, tenderness, or wetness, the immediate nursing action is to hold the drug, notify the provider, and check their CK levels.

That is a huge clinical takeaway.

Hold the drug, check the CK.

Exactly.

Also, a vital safety alert from the text.

Statins are category X, strictly contraindicated in pregnancy.

Yes, the developing fetus requires immense amounts of cholesterol for cellular and brain development.

Inhibiting that pathway is disastrous.

And we absolutely cannot forget drug interactions.

Because statins are heavily metabolized by the CYP3A4 enzyme in the liver.

Ah, CYP3A4.

The liver's chemical garbage disposal.

Precisely.

If you give a patient a drug that inhibits CYP3A4, like the antibiotic erythromycin, or the HIV drug ritonavir, or even just a glass of grapefruit juice, the garbage disposal stops working.

And the statin just builds up.

Right.

The statin isn't metabolized, it builds up to toxic levels in the blood, and the risk for rhabdomyolysis just skyrockets.

So, statins are clearly the heavy hitters.

But what happens if a patient simply cannot tolerate them, you know, because of those muscle aches, or if their LDL levels are just stubbornly high despite maximum statin therapy?

Then we move down the algorithmic ladder to the binders, specifically the bile acid sequesterers.

Okay, the prototype drug here is colisalum, right?

Yes.

We also have older agents in this class, like cholesterolamine, but colisalum is the standard today, because it has fewer side effects.

It is a biologically inert, non -absorbable resin.

I picture this drug like a giant,

sticky snowball rolling through the digestive tract.

I mean, that doesn't get absorbed into the bloodstream at all.

No, it just stays in the gut.

It just rolls through the intestines, and because it's highly charged, it binds tightly to bile acids, forming this insoluble complex that eventually just gets excreted in the feces.

And remember, our physiology from earlier bile acids are synthesized from cholesterol.

By trapping the bile in the gut and forcing it out in the feces, you are actively depleting the liver's bile reserve.

So the liver has to make more.

Exactly.

The liver realizes it needs to make more bile, so it pulls LDL cholesterol out of the bloodstream to use as the raw material.

And blood LDL goes down because the liver is consuming it.

Right, again.

But because it's essentially a sticky snowball moving through the gut, there are significant nursing implications, right?

It doesn't just grab bile.

Absolutely not.

The older drugs especially, like colostermine, they don't just bind bile.

They indiscriminately bind other medications like warfarin, digoxin, and even fat -soluble vitamins.

Just blocking them from being absorbed.

Yes.

So the crucial patient teaching point here is about medication timing.

You must administer other oral medications either one hour before or four hours after a bile acid sequestrant.

One hour before.

Or four hours after.

Got it.

And because the resin moving through the intestines,

the main adverse effect is severe constipation, right?

Yeah.

Patients need to be counseled to increase their fluids and dietary fiber.

Okay.

So we have a drug that stops bile reabsorption.

But what about a drug that stops cholesterol absorption directly from the food we eat?

That brings us to our next class.

The blocker.

Azetamabe.

This drug has a very unique mechanism of action.

It acts directly on the brush border of the small intestine to inhibit dietary cholesterol from being absorbed into the body.

It's basically a bouncer at the door of the intestines.

Just saying, sorry dietary cholesterol, you aren't on the guest list.

That's essentially it.

And it's generally well tolerated on its own, but it comes with major clinical warnings when used in combination therapy.

What kind of warnings?

If you combine azetamabe with a statin,

the risk for liver damage and myopathy goes up.

And if you combine it with fibroids, the risk for gallstones increases significantly.

That's a vital warning.

Yeah.

You know, you mentioned that combining it with fibroids increases the risk of gallstones.

Let's pivot to that specific class, the fibroids, because their primary target is entirely different than the statins or the binders.

They are.

The prototype for the fibroid class is Gemfibrozil.

Fibroids are the most effective drugs we have for lowering triglycerides, which, remember, are carried in those VLDL particles.

They also raise HDL, but they do virtually nothing to lower the bad LDL cholesterol.

The text explains they work by interacting with a specific receptor pathway in the liver called PPAR -alpha, which basically accelerates the clearance of VLDLs.

So wait, if they don't lower the bad LDL that causes atherosclerosis, why are we prescribing them?

What's the clinical indication?

This brings us back to that physiology rule we established earlier about VLDLs.

Very high triglycerides over 500 cause acute pancreatitis.

Oh, right.

The toxic fatty acids.

Yes.

So fibroids are prescribed primarily to lower VLDL levels to prevent pancreatitis in severely hyper -triglyceridemic patients.

But they carry serious risks.

We mentioned gallstones.

Why do they cause gallstones?

Because fibroids increase the concentration of cholesterol excreted into the biliary tract, this supersaturates the bile, leading to the crystallization of gallstones.

Makes sense.

They can also cause myopathy and liver injury.

But there is a massive red alert drug interaction for nursing students to know here involving blood thinners.

Let me guess.

Warfarin.

Yes.

Gemfibrozole displaces warfarin from plasma aldium.

Let's translate the chemistry on that for a second.

Warfarin is an anticoagulant.

It travels through the blood, mostly attached to a carrier protein called albumin.

Right.

And while it's attached, it's inactive.

But then gemfibrozole comes along, competes for those same binding sites, and literally kicks the warfarin off the albumin.

Now you suddenly have a surge of free -floating active warfarin in the blood.

Which drastically increases the anticoagulant effect.

It is a profound bleeding risk.

Nurses must monitor the patient's PTI and R coagulation labs incredibly closely, and the provider will almost certainly need to lower the warfarin dose.

Incredible cause and effect mechanism there.

All right.

We've covered the traditional oral medications.

Let's look at the cutting edge therapies in the text.

The injectables and the newcomers that target the receptors and enzymes directly.

First up, PCSK9 inhibitors like Illiricumab.

So to understand how these work, you need to know what PCSK9 actually is.

It's a regulatory protein in the body that normally binds to LDL receptors on the liver, causing them to be degraded.

It degrades the receptors.

Yeah, it's the body's way of preventing the liver from taking in too much cholesterol.

But in patients with high cholesterol, we want those receptors working overtime.

Exactly.

So Illiricumab is a monoclonal antibody.

It's administered as a subcutaneous injection that binds to and inhibits the PCSK9 protein.

So it stops the inhibitor.

Right.

By neutralizing the inhibitor, you keep the liver's receptors active and present on the cell surface much longer, freeing them up to clear substantial amounts of LDL from the blood.

But because it's a monoclonal antibody, which means it's a large foreign protein, patients can develop immunogenicity, right?

Their immune system literally creates antibodies against the drug.

Yes, which can lead to significant injection site reactions or systemic hypersensitivity.

Okay.

What else is new?

Then we have the absolute newest class discussed in the text, ACL inhibitors with Bempadoic acid as the prototype.

Bempadoic acid.

Now this one works similarly to statins by decreasing cholesterol synthesis, but it inhibits an enzyme called ATP citrate -lias, or ACL, which is much higher up in the biological pathway than H and G CoA reductase.

That's right.

But the side effects here are wild.

They are very specific.

Because of how it alters cellular metabolism, Bempadoic acid can inhibit the renal excretion of uric acid.

Which causes hyperuricemia.

Yes, which leads to severe gout.

But more bizarrely, it has a documented risk of actual tendon rupture.

Wait, tendon rupture?

Yes.

Specifically, the Achilles tendon or the rotator cuff, especially in patients over 60.

The metabolic shifts seem to physically weaken the tendon matrix.

You take a cholesterol pill and your Achilles tendon snaps.

Yeah.

I mean, that is exactly why nursing assessment and knowing what to look for is so absolutely critical.

It really is.

Before we wrap up the pharmacology, I want to quickly touch on the dietary supplements.

Because when you're a nurse, patients are definitely going to ask you about the over -the -counter options they saw on a commercial or at the grocery store.

Oh, for sure.

We have to address fish oil and plant sterols.

Fish oil preparations like Lavazza and Vasepa contain high doses of EPA and DHA omega -3 fatty acids.

And people just take those like vitamins.

They do.

But they are actually FDA approved to treat severely high triglycerides.

But the nursing watch out here is that large doses of omega -3s impair platelet function, Yes.

They physically alter the platelet membrane, which prolongs bleeding time.

So if your patient is on aspirin or a blood thinner, fish oil is not just a harmless natural supplement.

What about plant stanols?

Well, you'll find these added to functional foods like benicol margarine.

Because their chemical structure is really similar to cholesterol, they compete for absorption in the gut and can reduce intestinal cholesterol absorption slightly.

Okay, so a bit milder.

Yeah.

But the most dangerous supplement patients ask about is colistin.

Ah, red yeast rice.

Yes.

Colistin is a dietary supplement made from fermented red yeast rice.

And its active ingredient is literally chemically identical to lavastatin.

Wait, so it's just a statin?

It is a statin.

But because it's sold as an unregulated dietary supplement, the dosing is totally unpredictable and completely unmeasured.

Oh, wow.

Yeah, so patients might take it thinking it's a gentle, natural alternative, completely unaware that they are exposing themselves to statin toxicity, myopathy, and liver damage.

Especially if they are already taking a prescribed statin.

Exactly.

Nurses must actively screen for red yeast rice during medication reconciliation.

Natural does not always mean safe.

Alright, we have covered a tremendous amount of ground today.

Let's land this plane with our rapid -fire summary of major nursing implications directly from the chapter's conclusion.

Okay, here is your clinical checklist.

Always obtain baseline lipid panels, LFTs for liver function, and CK labs for muscle breakdown before initiating therapy.

2.

Patient teaching is paramount lipid therapy is a lifelong commitment.

If they stop the drug, their lipid levels will shoot right back up to pre -treatment levels.

3.

Remind patients to take their statins in the evening when the liver is working hardest to synthesize cholesterol.

4.

Separate bile acid sequestrants like cholesivellum from all other oral meds by at least an hour before or four hours after to prevent absorption issues.

And 5.

Instruct patients to report any unexplained muscle pain, tenderness, or yellowing of the skin immediately.

Absolutely critical.

To close us out, I want to leave you with a lingering, kind of provocative question straight from the textbook.

We know that statins definitively improve clinical outcomes.

They stabilize plaques, prevent heart attacks, and save lives.

The data is rock solid on that.

But some of these other drugs we discussed, like the fibrates or adesadabes, well, they fix the lab numbers on the chart, but they haven't actually proven to reduce cardiovascular mortality in the exact same way.

And this raises an incredibly important question for the future of medicine.

I mean, it makes you wonder, are some of these lipid abnormalities, like low HDL or mildly elevated triglycerides, the true root cause of cardiovascular disease?

Or are they just an associated symptom?

Exactly.

Are they just a biochemical marker of some deeper underlying metabolic dysfunction that we just don't fully understand yet?

Like are we just clearing the traffic jam without fixing the broken road underneath?

Something to mull over as you study.

From all of us here at the Deep Drive and the Last Minute Lecture Team, thank you so much for joining us.

Good luck on your pharmacology exam, and we'll see you out on the clinical floor.